APA (7th ed.) Citation

HK, G., S, P., FT, L., NC, T., M, A., ST, L., . . . AM, S. (2022). A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. Investigational new drugs, 40(4), 747. https://doi.org/10.1007/s10637-022-01237-3

Chicago Style (17th ed.) Citation

HK, Gan, et al. "A Phase 1 Safety and Bioimaging Trial of Antibody DS-8895a Against EphA2 in Patients with Advanced or Metastatic EphA2 Positive Cancers." Investigational New Drugs 40, no. 4 (2022): 747. https://doi.org/10.1007/s10637-022-01237-3.

MLA (9th ed.) Citation

HK, Gan, et al. "A Phase 1 Safety and Bioimaging Trial of Antibody DS-8895a Against EphA2 in Patients with Advanced or Metastatic EphA2 Positive Cancers." Investigational New Drugs, vol. 40, no. 4, 2022, p. 747, https://doi.org/10.1007/s10637-022-01237-3.